Alpha1-antitrypsin levels and phenotypes and hepatitis B serology in liver cancer

Citations of this article
Mendeley users who have this article in their library.
Get full text


Serum levels of alpha 1-antitrypsin (α1AT) were measured by radial immunodiffusion and phenotypes were determined by electrofocusing in acrylamide gel in 39 patients with hepatocellular carcinoma (HCC) positive for serum hepatitis B surface antigen (HBsAg), 41 patients with HCC negative for serum HBsAg, and 160 age- and sex-matched hospital controls. There was no difference between the control series and either of the two HCC groups with respect to α1AT phenotype pattern, also, there was no evidence of association between HCC and either the M2 allele or any of the α1AT deficiency phenotypes. However, HCC cases negative for HBsAg had significantly higher serum α1AT values (mean 665 ± 26 mg 100 ml-1) than HCC cases positive for HBsAg (mean 571 ± 23 mg 100 ml-1), who in turn, had significantly higher α1AT values than hospital controls (mean 434 ± 13 mg 100 ml-1). These results indicate that in Greece, as in other high HCC incidence countries, genetically determined α1AT deficiency is not aetiologically important, the increase of serum α1AT is an important correlate of HCC with possible aetiologic significance and diagnostic potential and HBsAg-positive HCC and HBsAg-negative HCC are manifest differently as well as being aetiologically distinct. © 1984 The Macmillan Press Ltd.




Sparos, L., Tountas, Y., Chapuis-Cellier, C., Theodoropoulos, G., & Trichopoulos, D. (1984). Alpha1-antitrypsin levels and phenotypes and hepatitis B serology in liver cancer. British Journal of Cancer, 49(5), 567–570.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free